ClinicalTrials.gg
CompletedNCT05603195Updated Oct 1, 2024

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

A Phase 1 interventional study of REGN7508 (IV) and REGN7508 (SC) in Healthy Volunteer, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is researching an experimental drug called REGN7508 (called "study drug"). The aim of this study is to see how safe and tolerable the study drug is in healthy participants.

This study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Healthy Volunteer

Keywords

  • Thrombotic disorders
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. between 18.0 and 32.5 kg/m2 (inclusive) at the screening visit
  2. Judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and echocardiograms (ECGs) performed at screening and/or prior to administration of initial dose of study drug
  3. Participant is in good health based on laboratory safety testing obtained at the screening visit and/or prior to administration of initial dose of study drug
  4. Normal (aPTT), normal prothrombin time (PT), and normal counts at screening period and at the day -1 visit as defined by the local laboratory
  5. value ≥11.0 g/dL for females and ≥12.9 g/dL for males at the screening and day 1 visits

Key Exclusion Criteria:

  1. History of any major surgical procedure or physical trauma, in the opinion of the investigator, that may pose a risk to the participant by study participation
  2. Whole blood donation within the previous 56 days or plasma donation within the previous 7 days prior to the screening visit
  3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, neurological, or dermatologic disease, as assessed by the investigator, that may confound the results of the study or poses an additional risk to the participant by study participation, as defined in the protocol
  4. Estimated (eGFR) of \<60 mL/min/1.73m2 at screening
  5. Current smoker or former smoker, including e-cigarettes, who stopped smoking within 12 months prior to the screening visit
  6. Confirmed positive drug test result at the screening visit and/or prior to randomization or a history of drug abuse within a year prior to the screening visit
  7. History of alcohol abuse within the last 2 years prior to the day 1 visit
  8. Any , except for nonmelanoma skin cancer or cervical/anus in situ, that have been resected with no evidence of disease for 3 years prior to the screening visit
  9. History of significant multiple and/or severe allergies (eg, latex gloves) or has had an anaphylactic reaction to prescription or nonprescription drugs or food

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Cohort 1 Lowest IV Dose

    Randomized 3:1

    Drug: REGN7508 (IV) · Drug: Matching Placebo (IV)

  • Experimental
    Cohort 2 Low IV Dose

    Randomized 3:1

    Drug: REGN7508 (IV) · Drug: Matching Placebo (IV)

  • Experimental
    Cohort 3 Mid IV Dose

    Randomized 3:1

    Drug: REGN7508 (IV) · Drug: Matching Placebo (IV)

  • Experimental
    Cohort 4 High IV Dose

    Randomized 3:1

    Drug: REGN7508 (IV) · Drug: Matching Placebo (IV)

  • Experimental
    Cohort 5 Higher IV Dose

    Randomized 3:1

    Drug: REGN7508 (IV) · Drug: Matching Placebo (IV)

  • Experimental
    Cohort 6 High SC Dose

    Randomized 3:1

    Drug: REGN7508 (SC) · Drug: Matching Placebo (SC)

  • Experimental
    Cohort 7 Higher SC Dose

    Randomized 3:1

    Drug: REGN7508 (SC) · Drug: Matching Placebo (SC)

  • Experimental
    Optional: Cohort 8 Highest IV or SC Dose

    Randomized 3:1

    Drug: REGN7508 (IV) · Drug: REGN7508 (SC) · Drug: Matching Placebo (IV) · Drug: Matching Placebo (SC)

  • Experimental
    Cohort 9 High SC Dose

    Randomized 3:1

    Drug: REGN7508 (SC) · Drug: Matching Placebo (SC)

  • Experimental
    Optional: Cohort 10 Highest SC Dose

    Randomized 3:1

    Drug: REGN7508 (SC) · Drug: Matching Placebo (SC)

Interventions

  • Administered sequential, ascending single intravenous (IV) dose

  • Administered sequential, ascending single subcutaneous (SC) dose

  • DrugMatching Placebo (IV)

    Administered sequential, ascending single intravenous (IV) dose

  • DrugMatching Placebo (SC)

    Administered sequential, ascending single subcutaneous (SC) dose

06

What researchers measure

Primary outcomes

  1. Incidences of treatment-emergent adverse events (TEAE)

    Treatment-emergent adverse events are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.

    Time frame: Up to 36 days

  2. Severity of TEAE

    Treatment-emergent adverse events are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.

    Time frame: Up to 36 days

Secondary outcomes

  1. Change from baseline in activated partial thromboplastin time (aPTT)

    Time frame: Up to 36 days

  2. Change from baseline in prothrombin time (PT)

    Time frame: Up to 36 days

  3. Concentrations of total REGN7508 in serum

    Time frame: Up to 36 days

  4. Concentrations of functional REGN7508 in plasma

    Time frame: Up to 36 days

  5. Absolute concentration and change from baseline in total Factor XI (FXI) concentrations

    Time frame: Up to 36 days

  6. Absolute concentration and change from baseline in free FXI concentrations

    Time frame: Up to 36 days

  7. Incidence of antidrug antibodies (ADAs) to REGN7508 over time

    Time frame: Up to 36 days

07

Study locations

1 site
  • Labcorp Clinical Research Unit
    Leeds, LS2 9LH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Sep 2024, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 2, 2022
StartActual
Jan 12, 2023
Primary completionActual
Sep 17, 2024
CompletionActual
Sep 17, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05603195
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Jan 12, 2023
Primary completion
Sep 17, 2024
Completion
Sep 17, 2024
Last update
Oct 1, 2024

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenvacibart

Start the discussion